Jeffrey Miceli

1.5k total citations
24 papers, 1.0k citations indexed

About

Jeffrey Miceli is a scholar working on Psychiatry and Mental health, Cardiology and Cardiovascular Medicine and Molecular Biology. According to data from OpenAlex, Jeffrey Miceli has authored 24 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 6 papers in Cardiology and Cardiovascular Medicine and 5 papers in Molecular Biology. Recurrent topics in Jeffrey Miceli's work include Schizophrenia research and treatment (9 papers), Cardiac electrophysiology and arrhythmias (5 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). Jeffrey Miceli is often cited by papers focused on Schizophrenia research and treatment (9 papers), Cardiac electrophysiology and arrhythmias (5 papers) and Neurotransmitter Receptor Influence on Behavior (4 papers). Jeffrey Miceli collaborates with scholars based in United States, United Kingdom and Canada. Jeffrey Miceli's co-authors include Thomas Shiovitz, Richard Anziano, Lloyd Knapp, R. Scott Obach, Christine Beedham, Richard P. Allen, Diego García‐Borreguero, John J. Sramek, Edmund P. Harrigan and Karen R. Reeves and has published in prestigious journals such as New England Journal of Medicine, Journal of the American Academy of Child & Adolescent Psychiatry and SLEEP.

In The Last Decade

Jeffrey Miceli

23 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jeffrey Miceli United States 17 345 262 246 239 184 24 1.0k
Stanley W. Carson United States 21 159 0.5× 155 0.6× 112 0.5× 143 0.6× 75 0.4× 54 1.3k
Jonathan G. Leung United States 15 339 1.0× 136 0.5× 258 1.0× 113 0.5× 94 0.5× 92 1.0k
Joris Berwaerts United States 23 880 2.6× 135 0.5× 200 0.8× 86 0.4× 136 0.7× 49 1.4k
Richard E. Gammans United States 19 162 0.5× 442 1.7× 154 0.6× 60 0.3× 164 0.9× 42 1.6k
Chun-Hsin Chen Taiwan 24 430 1.2× 105 0.4× 110 0.4× 73 0.3× 44 0.2× 53 1.3k
Brendan Kelley United States 16 302 0.9× 81 0.3× 192 0.8× 118 0.5× 79 0.4× 33 973
Ed Whalen United States 18 649 1.9× 102 0.4× 494 2.0× 299 1.3× 60 0.3× 59 2.0k
François Paillé France 16 88 0.3× 388 1.5× 251 1.0× 35 0.1× 75 0.4× 65 1.0k
Julia Schweiger United States 10 429 1.2× 61 0.2× 197 0.8× 42 0.2× 43 0.2× 24 1.0k
G.J.M. Walstra Netherlands 16 590 1.7× 64 0.2× 80 0.3× 259 1.1× 47 0.3× 25 1.1k

Countries citing papers authored by Jeffrey Miceli

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Miceli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Miceli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Miceli more than expected).

Fields of papers citing papers by Jeffrey Miceli

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Miceli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Miceli. The network helps show where Jeffrey Miceli may publish in the future.

Co-authorship network of co-authors of Jeffrey Miceli

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Miceli. A scholar is included among the top collaborators of Jeffrey Miceli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Miceli. Jeffrey Miceli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fullerton, Terence, Brendon Binneman, William David, et al.. (2018). A Phase 2 clinical trial of PF-05212377 (SAM-760) in subjects with mild to moderate Alzheimer’s disease with existing neuropsychiatric symptoms on a stable daily dose of donepezil. Alzheimer s Research & Therapy. 10(1). 38–38. 27 indexed citations
2.
Allen, Richard P., Diego García‐Borreguero, Olli Polo, et al.. (2014). Comparison of Pregabalin with Pramipexole for Restless Legs Syndrome. New England Journal of Medicine. 370(7). 621–631. 152 indexed citations
3.
García‐Borreguero, Diego, Jeffrey Patrick, Sarah Dubrava, et al.. (2014). Pregabalin Versus Pramipexole: Effects on Sleep Disturbance in Restless Legs Syndrome. SLEEP. 37(4). 635–643. 60 indexed citations
4.
Rickels, Karl, et al.. (2012). Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment. International Clinical Psychopharmacology. 27(3). 142–150. 44 indexed citations
5.
Camm, A. John, Onur N. Karayal, Herbert Y. Meltzer, et al.. (2012). Ziprasidone and the Corrected QT Interval. CNS Drugs. 26(4). 351–365. 28 indexed citations
6.
7.
Miceli, Jeffrey, et al.. (2010). Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 30(2). 127–135. 29 indexed citations
8.
Allen, Richard P., Adina Soaita, Lloyd Knapp, et al.. (2010). A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Medicine. 11(6). 512–519. 68 indexed citations
9.
DelBello, Melissa P., Mark Versavel, Kathleen Ice, David Keller, & Jeffrey Miceli. (2008). Tolerability of Oral Ziprasidone in Children and Adolescents with Bipolar Mania, Schizophrenia, or Schizoaffective Disorder. Journal of Child and Adolescent Psychopharmacology. 18(5). 491–499. 42 indexed citations
10.
Sallee, Floyd R., et al.. (2006). Single-Dose Pharmacokinetics and Safety of Ziprasidone in Children and Adolescents. Journal of the American Academy of Child & Adolescent Psychiatry. 45(6). 720–728. 27 indexed citations
11.
Miceli, Jeffrey, Keith D. Wilner, Suzanne K. Swan, & Thomas G. Tensfeldt. (2005). Pharmacokinetics, Safety, and Tolerability of Intramuscular Ziprasidone in Healthy Volunteers. The Journal of Clinical Pharmacology. 45(6). 620–630. 28 indexed citations
12.
Harrigan, Edmund P., Jeffrey Miceli, Richard Anziano, et al.. (2004). A Randomized Evaluation of the Effects of Six Antipsychotic Agents on QTc, In the Absence and Presence of Metabolic Inhibition. Journal of Clinical Psychopharmacology. 24(1). 62–69. 258 indexed citations
13.
Beedham, Christine, Jeffrey Miceli, & R. Scott Obach. (2003). Ziprasidone Metabolism, Aldehyde Oxidase, and Clinical Implications. Journal of Clinical Psychopharmacology. 23(3). 229–232. 101 indexed citations
14.
Beedham, Christine, Jeffrey Miceli, & R. Scott Obach. (2003). . Journal of Clinical Psychopharmacology. 23(3). 229–232. 16 indexed citations
15.
Sallee, Floyd R., et al.. (2003). Pharmacodynamics of Ziprasidone in Children and Adolescents: Impact on Dopamine Transmission. Journal of the American Academy of Child & Adolescent Psychiatry. 42(8). 902–907. 29 indexed citations
16.
Wilner, Keith D., et al.. (2002). The Anxiolytic Effect of the Novel Antipsychotic Ziprasidone Compared With Diazepam in Subjects Anxious Before Dental Surgery. Journal of Clinical Psychopharmacology. 22(2). 206–210. 20 indexed citations
17.
Hamelin, Bettina A., Louis Laplante, Jeffrey Miceli, et al.. (1998). The Effect of Timing of a Standard Meal on the Pharmacokinetics and Pharmacodynamics of the Novel Atypical Antipsychotic Agent Ziprasidone. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 18(1). 9–15. 45 indexed citations
18.
Miceli, Jeffrey, et al.. (1997). 5HT2 and D2 receptor occupancy of ziprasidone in healthy volunteers. Schizophrenia Research. 24(1-2). 178–178. 1 indexed citations
19.
Mirochnick, Mark, Jeffrey Miceli, Paul A. Kramer, Dennis J. Chapron, & John R. Raye. (1990). Renal Response to Furosemide in Very Low Birth WeightInfants during Chronic Administration. Developmental Pharmacology and Therapeutics. 15(1). 1–7. 26 indexed citations
20.
Miceli, Jeffrey, et al.. (1989). High-performance liquid chromatographic assay for a novel psychotropic drug (CI-943) in cynomolgus monkey plasma. Journal of Chromatography B Biomedical Sciences and Applications. 496(2). 493–499. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stanley W. Carson Breakdown of academic impact, for papers by Jonathan G. Leung Breakdown of academic impact, for papers by Joris Berwaerts Breakdown of academic impact, for papers by Richard E. Gammans Breakdown of academic impact, for papers by Chun-Hsin Chen Breakdown of academic impact, for papers by Brendan Kelley Breakdown of academic impact, for papers by Ed Whalen Breakdown of academic impact, for papers by François Paillé Breakdown of academic impact, for papers by Julia Schweiger Breakdown of academic impact, for papers by G.J.M. Walstra
Rankless by CCL
2026